| abstract |
An oligomer having a complementary sequence of 7-10 nucleotides to a microRNA target. The oligomer has at least 70 percent of the nucleotides selected from Locked Nucleic Acid (LNA) or 2' substituted nucleotide analogues, wherein at least 50% of the nucleotides are LNA and the oligomer has at least one phosphorothioate internucleoside linkage. The microRNA target can be hsa-miR-122. The oligomer can be used to treat hepatitis C virus infection or hypercholesterolemia. |